In a bid to bolster its oncology pipeline, GlaxoSmithKline (GSK) has entered into a collaboration agreement with iTeos Therapeutics to develop and commercialise the latter’s monoclonal antibody, EOS-448, for the treatment of advanced solid tumours. The deal, which is worth up to US$2.75 B, gives GSK access to an anti-TIGIT antibody that targets tumor cells. With this deal GSK will be able to mark its presence in the TIGIT monoclonal antibody segmentwhich is already occupied by companies such as Roche, Bristol-Mayer-Squibb and Merck & Co.